The global neutropenia treatment market was valued USD 15.37 Billion in 2022 and is expected to rise to USD 23.14 Billion by 2030 at a CAGR of 5.19%. The study examines global neutropenia treatment market drivers, restraints/challenges, and their impact on demand throughout the projection period. The research also examines neutropenia treatment possibilities.
Global Neutropenia Treatment Market: Overview
In Global Neutropenia Treatment Market Report, Neutropenia is a blood condition that is characterized by low levels of neutrophils that help to protect the body from infection. Neutropenia can be due to infection or as a result of cancer treatment. Depending on the number of neutrophils in the sample of the blood, neutropenia is categorized as severe, moderate, or mild. Some types of neutropenia may not require treatment but in the case of febrile neutropenia, treatment is essential as it may also lead to death.
Get a Free Sample : https://www.zionmarketresearch.com/sample/neutropenia-treatment-market
Global Neutropenia Treatment Market: Growth Factors
Major factors that are driving the growth of the global market are the rise in prevalence of chemotherapy-induced neutropenia, the growing need for efficient & effective treatment, and the easy availability of the drugs through online pharmacies. As per the data published by CDC, in the United States, every year nearly 650,000 cancer patients undergo chemotherapy in an outpatient oncology clinic. These patients are at a high risk of developing neutropenia which is recognized as the most serious hematologic toxicity as a result of cancer treatment with chemotherapy. This leads to disruptions in chemotherapy schedules, hospitalization, and in some cases death.
All such factors coupled with the growing prevalence of infections such as sepsis, tuberculosis & hepatitis, and autoimmune diseases including rheumatoid arthritis, lupus, and Crohn’s disease are fostering the growth of the global neutropenia treatment market. In addition to this, a rise in the number of clinical trials for neutropenia treatment and an increase in mergers & acquisitions by the pharmaceuticals to expand the business & pipeline drugs are also some of the major factors that are contributing to the growth of the global market.
Moreover, factors such as heavy investments in R&D activities and the rise in outsourcing of drug discovery & development projects are also contributing to the growth of the global market. Furthermore, technological advancements for the development of innovative products for effective treatment can provide several opportunities for the growth of the global neutropenia treatment market over the forecast period. However, strict regulations imposed by the regulatory bodies for the approval may limit the growth of the global neutropenia treatment market.
The global neutropenia treatment market is moderately affected by the outbreak of the Covid-19 pandemic. The shutdown of the manufacturing units, temporary halt on clinical trials, and postponement of non-emergency cases due to the strict lockdown and restriction on movement in the first half of the year 2020 have affected the manufacture of drugs & biologics necessary for the neutropenia treatment. On the other hand, the online sales of drugs and drop in the platelet count in some Covid-19 positive patients are witnessed to support the growth of the global market during the pandemic.
Global Neutropenia Treatment Market: Segmentation
The global neutropenia treatment market is divided based on treatment, distribution channel, and region.
Based on treatment, the global neutropenia treatment market is split into antivirals, anti-fungals, antibiotics, and colony-stimulating factors. Among these, the colony-stimulating factor segment is anticipated to lead the global market due to the rise in focus of manufacturers on colony-stimulating factor-based drugs.
The distribution channel is bifurcated into online pharmacies, retail pharmacies, and hospital pharmacies. Among these, the hospital pharmacies segment is expected to hold the largest share in the market.
Global Neutropenia Treatment Market: Regional Analysis
North America is anticipated to dominate the global neutropenia treatment market during the forecast period. The rise in prevalence of chemotherapy-induced neutropenia especially in the US is the chief factor that is spurring the growth of the market in this region. In addition to this, the presence of advanced technology, huge investment in research & development, and favorable reimbursement policies are also some of the factors that are fueling the growth of the market in North America. Asia Pacific is estimated to be the fastest-growing region in the market. This is attributing to the rise in expenditure on healthcare, growing cases of cancer, and growing prevalence of infections in under-developed countries.
Directly Purchase a copy of the report with TOC @
Global Neutropenia Treatment Market: Competitive Players
- Teva Pharmaceutical Industries Ltd.
- Spectrum Pharmaceuticals
- Partner Therapeutics
- Novartis AG
- Mylan N.V.
- Cellerant Therapeutics
- Kyowa Kiri
Global Neutropenia Treatment Market: Segment Analysis
- Colony-Stimulating Factors
By Distribution Channel
- Online Pharmacies
- Retail Pharmacies
- Hospital Pharmacies
- North America
- The U.S.
- The UK
- Rest of Europe
- Asia Pacific
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- South Africa
- Rest of Middle East & Africa
What Reports Provides
- Full in-depth analysis of the parent market
- Important changes in market dynamics
- Segmentation details of the market
- Former, on-going, and projected market analysis in terms of volume and value
- Assessment of niche industry developments
- Market share analysis
- Key strategies of major players
- Emerging segments and regional markets
- Testimonials to companies in order to fortify their foothold in the market.
USA: +1 347 690-0211
United Kingdom: +44 2032 894158
Japan: +81 50 5806 9039
India: +91 7768 006 007